The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx

Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson JNJ and Roche Holding AG RHHBY each reported fairly robust results.

Four healthcare stocks, including biotechs and medical device makers, debuted on Wall Street this week, raising $413.3 million in gross proceeds.

Ocugen, Inc. OCGN was among the biggest gainers of the week, having advanced over 110% on the back of a positive clinical readout for a partnered COVID-19 vaccine candidate.

Here are the key catalysts for the unfolding week:


International Organization for Medical Physics', or IOMP, International Medical Physics Week: April 26-30
UBS Asia Virtual Healthcare Summit: April 27-29
B. Riley's Neuroscience Investor Conference: April: April 28—29
2021 Society of Biological Psychiatry, or SOBP, annual meeting: April 29-May 1
Association for Research In Vision and Ophthalmology, or ARVO, 2021 Virtual Meeting: May 1-7


The Food and Drug Administration is scheduled to announce its verdict on Sol-Gel Technologies Ltd.'s SLGL new drug application for Epsolay in the treatment of inflammatory lesions of rosacea. The PDUFA date, or the deadline for announcing the decision, is Monday.

The FDA will also rule on Protalix BioTherapeutics, Inc.'s PLX biologic license application for pegunigalsidase alfa in Fabry disease. The PDUFA date is set for Tuesday.

By Thursday, the regulatory agency is mandated to make a decision on Ardelyx, Inc.'s ARDX new drug application for tenapanor in hyperphosphatemia.

Related Link: BofA Says GlaxoSmithKline's Decision To Halt Feladilimab Studies Is Disappointing

Clinical Readouts/Presentations

Nanobiotix S.A. NBTX is scheduled to present at the IOMP's physics week, further data from the Phase 1 expansion data for NBTXR3 in head and neck cancer.

Cyclerion Therapeutics, Inc. CYCN will host a webinar at 8 a.m., Tuesday, to provide a corporate update on clinical programs for its CY6463 in Alzheimer's disease with vascular pathology and mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes.

Trillium Therapeutics Inc. TRIL will host its virtual R&D Day for analysts and investors at 10:00 am – 1:00 pm on Wednesday, wherein it will provide a clinical update for TTI-622 in refractory lymphoma or multiple myeloma, and TTI-621 in diffuse Large B-cell Lymphoma (DLBCL), cutaneous T-cell lymphoma.

Aptinyx Inc. APTX is due to present at the SOBP annual meeting, data from the Phase 2a exploratory study of NYX-783 in posttraumatic stress disorder.

Annovis Bio, Inc. ANVS is scheduled to release in April interim data for ANVS401 in Alzheimer's and Parkinson's diseases.

Lineage Cell Therapeutics, Inc. LCTX is set to present at the ARVO annual meeting updated interim results from a Phase 1/2a study of its lead product candidate, OpRegen, a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration.



Brainstorm Cell Therapeutics Inc. BCLI (before the market open)
Masimo Corporation MASI (after the close)


Eli Lilly and Company LLY (before the market open)
AtriCure, Inc. ATRC (after the close)
Amgen Inc. AMGN (after the close)
Illumina, Inc. ILMN (after the close)


Boston Scientific Corporation BSX (before the market open)
Surmodics, Inc. SRDX (before the market open)
Integra LifeSciences Holdings Corporation IART (before the market open)
Alkermes plc ALKS (before the market open)
Apellis Pharmaceuticals, Inc. APLS (after the close)
Alimera Sciences, Inc. ALIM (after the close)
OPKO Health, Inc. OPK (after the close)
Hologic, Inc. HOLX (after the close)
Viking Therapeutics, Inc. VKTX (after the close)


Syneos Health, Inc. SYNH (before the market open)
NovoCure Limited NVCR (before the market open)
West Pharmaceutical Services, Inc. WST (before the market open)
Merck & Co., Inc. MRK (before the market open)
Evelo Biosciences, Inc. EVLO (before the market open)
Baxter International Inc. BAX (before the market open)
Bristol-Myers Squibb Company BMY (before the market open)
Blueprint Medicines Corporation BPMC (before the market open)
Alnylam Pharmaceuticals, Inc. ALNY (before the market open)
Laboratory Corporation of America Holdings LH (before the market open)
Abiomed, Inc. ABMD (before the market open)
Amarin Corporation plc AMRN (before the market open)
Agios Pharmaceuticals, Inc. AGIO (before the market open)
ResMed Inc. RMD (after the close) (after the close)
MiMedx Group, Inc. MDXG (after the close)
BioMarin Pharmaceutical Inc. BMRN (after the close)
Pacific Biosciences of California, Inc. PACB (after the close)
Bio-Rad Laboratories, Inc. BIO (after the close)
Emergent BioSolutions Inc. EBS (after the close)
ChemoCentryx, Inc. CCXI (after the close)
DexCom, Inc. DXCM (after the close)
Gilead Sciences, Inc. GILD (after the close)
Merit Medical Systems, Inc. MMSI (after the close)
LeMaitre Vascular, Inc. LMAT (after the close)
MacroGenics, Inc. MGNX (after the close)
Vertex Pharmaceuticals Incorporated VRTX (after the close)
Seagen Inc. SGEN (after the close)


AbbVie Inc. ABBV (before the market open)

IPOs Quiet Period Expiries

Achilles Therapeutics plc ACHL

Related Link: Why This Bristol-Myers Squibb Stock Analyst Is Turning Bullish On The Pharma Company's Pipeline

Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsPenny StocksSmall CapFDA